{"id":19339,"date":"2023-04-23T17:24:00","date_gmt":"2023-04-23T09:24:00","guid":{"rendered":"https:\/\/flcube.com\/?p=19339"},"modified":"2024-12-22T19:07:11","modified_gmt":"2024-12-22T11:07:11","slug":"lees-pharmaceutical-holdings-ltd-reports-2022-revenues-and-pipeline-updates","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19339","title":{"rendered":"Lee’s Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates"},"content":{"rendered":"\n

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950<\/a>) has released its 2022 financial report, recording HKD 1.233 billion (USD 157 million) in revenues, marking a 2.6% year-on-year (YOY) decrease. In-licensed products contributed HKD 733 million (USD 93.73 million), accounting for 59.5% of total revenues, while patented drugs and generics made up 40.5% with HKD 500 million (USD 63.69 million). The company reported a net loss of HKD 54.42 million (USD 6.93 million), compared to a net profit of RMB 2.068 billion (USD 299.9 million) in 2021, primarily due to equity sales of subsidiary Zhaoke Ophthalmology Ltd (6622.HK). Research and development (R&D) investment fell by 24.1% YOY to HKD 352 million (USD 44.8 million).<\/p>\n\n\n\n

ANDA Approvals and New Drug Developments<\/strong>
During the period, Lee\u2019s Pharma obtained seven approvals for Abbreviated New Drug Applications (ANDAs) and drug importing filings in China. In March, the company received approval for Zingo (intradermal injection system of lidocaine hydrochloride powder) for topical analgesia in children aged 3 to 18 and adults. Additionally, INOmax (inhaled nitric oxide gas) was approved for the treatment of term infants with hypoxic respiratory failure and pulmonary hypertension, as well as premature infants over 34 weeks old.<\/p>\n\n\n\n

Strategic Partnerships and Licensing Deals<\/strong>
In July 2022, Lee\u2019s Pharma struck a licensing deal with Unicycive, securing exclusive rights to Renazorb (lanthanum dioxycarbonate) in the Chinese mainland, Hong Kong, and other Asian markets. The company also amended its licensing deal with BioQ to include ropivacaine and 5FU pre-loaded syringes. AU409, developed by Auransa Inc. and manufactured by its Guangzhou unit, obtained clinical trial approval in the United States in 2022.<\/p>\n\n\n\n

Robust Product Pipeline in Oncology<\/strong>
Lee\u2019s Pharma boasts a product pipeline exceeding 40 programs, including 6 innovative drugs and 4 generics in the oncology field. Socazolimab, a programmed-death ligand 1 (PD-L1) antibody, is undergoing Phase III studies in osteosarcoma and small cell lung cancer (SCLC) in China. The oral multi-kinase inhibitor zotiraciclib is in a Phase I study for glioblastoma, and topoisomerase I inhibitor gimatecan is in early clinical stages for ovarian cancer, SCLC, and pancreatic cancer in China.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its 2022 financial report, recording HKD…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,165],"class_list":["post-19339","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-lees-pharmaceutical"],"yoast_head":"\nLee's Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Lee's Pharmaceutical Holdings Ltd (HKG: 0950) has released its 2022 financial report, recording HKD 1.233 billion (USD 157 million) in revenues, marking a 2.6% year-on-year (YOY) decrease. In-licensed products contributed HKD 733 million (USD 93.73 million), accounting for 59.5% of total revenues, while patented drugs and generics made up 40.5% with HKD 500 million (USD 63.69 million). The company reported a net loss of HKD 54.42 million (USD 6.93 million), compared to a net profit of RMB 2.068 billion (USD 299.9 million) in 2021, primarily due to equity sales of subsidiary Zhaoke Ophthalmology Ltd (6622.HK). Research and development (R&D) investment fell by 24.1% YOY to HKD 352 million (USD 44.8 million).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19339\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lee's Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19339\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-23T09:24:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-22T11:07:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19339#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19339\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lee’s Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates\",\"datePublished\":\"2023-04-23T09:24:00+00:00\",\"dateModified\":\"2024-12-22T11:07:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19339\"},\"wordCount\":335,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"Lee's Pharmaceutical\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19339#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19339\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19339\",\"name\":\"Lee's Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-04-23T09:24:00+00:00\",\"dateModified\":\"2024-12-22T11:07:11+00:00\",\"description\":\"China-based Lee's Pharmaceutical Holdings Ltd (HKG: 0950) has released its 2022 financial report, recording HKD 1.233 billion (USD 157 million) in revenues, marking a 2.6% year-on-year (YOY) decrease. In-licensed products contributed HKD 733 million (USD 93.73 million), accounting for 59.5% of total revenues, while patented drugs and generics made up 40.5% with HKD 500 million (USD 63.69 million). The company reported a net loss of HKD 54.42 million (USD 6.93 million), compared to a net profit of RMB 2.068 billion (USD 299.9 million) in 2021, primarily due to equity sales of subsidiary Zhaoke Ophthalmology Ltd (6622.HK). Research and development (R&D) investment fell by 24.1% YOY to HKD 352 million (USD 44.8 million).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19339#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19339\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19339#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lee’s Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lee's Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates - Insight, China's Pharmaceutical Industry","description":"China-based Lee's Pharmaceutical Holdings Ltd (HKG: 0950) has released its 2022 financial report, recording HKD 1.233 billion (USD 157 million) in revenues, marking a 2.6% year-on-year (YOY) decrease. In-licensed products contributed HKD 733 million (USD 93.73 million), accounting for 59.5% of total revenues, while patented drugs and generics made up 40.5% with HKD 500 million (USD 63.69 million). The company reported a net loss of HKD 54.42 million (USD 6.93 million), compared to a net profit of RMB 2.068 billion (USD 299.9 million) in 2021, primarily due to equity sales of subsidiary Zhaoke Ophthalmology Ltd (6622.HK). Research and development (R&D) investment fell by 24.1% YOY to HKD 352 million (USD 44.8 million).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19339","og_locale":"en_US","og_type":"article","og_title":"Lee's Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=19339","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-04-23T09:24:00+00:00","article_modified_time":"2024-12-22T11:07:11+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19339#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19339"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lee’s Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates","datePublished":"2023-04-23T09:24:00+00:00","dateModified":"2024-12-22T11:07:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19339"},"wordCount":335,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","Lee's Pharmaceutical"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19339#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19339","url":"https:\/\/flcube.com\/?p=19339","name":"Lee's Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-04-23T09:24:00+00:00","dateModified":"2024-12-22T11:07:11+00:00","description":"China-based Lee's Pharmaceutical Holdings Ltd (HKG: 0950) has released its 2022 financial report, recording HKD 1.233 billion (USD 157 million) in revenues, marking a 2.6% year-on-year (YOY) decrease. In-licensed products contributed HKD 733 million (USD 93.73 million), accounting for 59.5% of total revenues, while patented drugs and generics made up 40.5% with HKD 500 million (USD 63.69 million). The company reported a net loss of HKD 54.42 million (USD 6.93 million), compared to a net profit of RMB 2.068 billion (USD 299.9 million) in 2021, primarily due to equity sales of subsidiary Zhaoke Ophthalmology Ltd (6622.HK). Research and development (R&D) investment fell by 24.1% YOY to HKD 352 million (USD 44.8 million).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19339#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19339"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19339#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lee’s Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19339"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19339\/revisions"}],"predecessor-version":[{"id":19340,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19339\/revisions\/19340"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}